Obicetrapib and renal function: A welcome signal, but not yet a kidney story

Read full text Summarise with VIRAT
Authors: Fotios Barkas, Kausik Kumar Ray
Cited by: 0
References: 9

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Chronic kidney disease (CKD) and atherosclerotic cardiovascular disease (ASCVD) frequently coexist and mutually amplify risk [1]. CKD development and progression share traditional ASCVD risk factors such as ageing, hypertension, diabetes, and obesity, but also include immune-mediated and inflammatory diseases among others [1]. There are differences with inflammation promoting structural and functional alterations within the renal microvasculature, glomeruli, and tubulointerstitium, ultimately leading to progressive nephron loss [1]. Beyond these mechanisms, disturbances in lipoprotein metabolism may also contribute to cardiovascular and renal injury.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Lipoproteins and Cardiovascular Health Blood Pressure and Hypertension Studies

Publication details

Journal / source
American Journal of Preventive Cardiology
Volume
27
Pages
101546–101546
Publication date
27 March 2026
Language
EN